ENOVEnovis CORP
Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Revenue
- $2.2B
- 6.7% YoY
- Operating margin
- -50.0%
- 36% YoY
- EBITDA
- $220M
- 45% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 5.8×
- $1.3B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear2% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear19% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.6B | $1.7B | $2.1B | $2.2B | 6.7% |
| Operating income | −$63M | −$71M | −$66M | −$776M | −$1.1B | 45% |
| Net income | $72M | −$13M | −$33M | −$825M | −$1.2B | 43% |
| Operating cash flow | $356M | −$56M | $135M | $114M | $217M | 91% |
| Capex | $104M | $105M | $122M | $181M | $197M | 9.2% |
| Stock-based comp | $35M | $39M | $34M | $30M | $33M | 11% |
| Buybacks | — | $0 | $0 | $5M | $4M | 27% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $474K · 5
- Open-market sells, 12 mo
- $0 · 0
- Net
- $474K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 41 | 79 |
| FY2024 | — | — | 67 | 79 |
| FY2023 | — | — | 85 | 75 |
| FY2022 | — | — | 81 | 79 |
| FY2021 | — | — | 120 | 104 |